

Review article

The key players in the arsenal of combating TB; reviewing the lead InhA inhibitors

Marwa M. Shaaban^{1*}, Hanan M. Ragab¹, Mohamed Teleb¹, Mona A. Mahran¹

¹Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt


*Corresponding author: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, El-Khartoom Square, Azarita, Alexandria, Egypt. Phone: (+203) 4868482. Fax: (+203) 4871668.

E-mail: marwa.mamdouh@alexu.edu.eg

Abstract:

After decades of decline, tuberculosis (TB) cases are continuously increasing worldwide, mostly in developing countries. Although it has not been regarded as fatal now, the TB situation may become worse with the appearance of multi-drug resistant strains (MDR-TB) that do not respond to the most common anti-TB medications, isoniazid and rifampicin. In certain cases,

even more severe drug-resistant TB may emerge. Extensively drug-resistant (XDR-TB), is a form of multidrug-resistant TB that also exhibits resistance to other anti-TB agents. The enoyl acyl carrier protein reductase (InhA) enzyme, a crucial regulator of TB mycolic acid biosynthesis, is attracting considerable attention as a druggable molecular target for combating TB and surmounting its resistance mechanisms. The current review covers the currently available anti-TB medications, including the most recently FDA-approved therapy, highlighting their modes of action. In addition, it provides brief structure-activity relationship data and resistance mechanisms halting their efficacy, with a special focus on InhA as an emerging anti-TB target, as well as an overviewing the most promising novel lead inhibitors classified according to their chemical entities.



Received: 25 February 2024

Accepted: 30 April 2024

Published: 5 May 2024

Keywords: Tuberculosis; InhA inhibitors; Triclosan; Triazoles; Pyrazoles**1. Introduction**

Tuberculosis (TB) is believed to be one of the most infectious diseases caused by *Mycobacterium tuberculosis* (*Mtb*)⁽¹⁾. It has been the main cause of morbidity and mortality for centuries⁽¹⁾. According to the most recent WHO global records, about 1.6 million deaths worldwide were attributed to TB in 2021. Worldwide, TB is the second leading infectious killer after COVID-19 (above AIDS)⁽²⁾. TB typically attacks the lungs but can also affect other parts of the body. It spreads through the air when people having an active TB infection cough or sneeze⁽³⁾. The continuously increasing records of the disease especially in developing countries⁽⁴⁾, together with the emergence of multi-drug resistant strains (MDR-TB) and the extensively drug-resistant (XDR-TB) TB⁽⁵⁾ directed efforts to invest in designing novel inhibitors for targeting the critical TB pathways. The enoyl acyl carrier protein reductase (InhA) enzyme comes at the top of the list as a crucial regulator of TB mycolic acid biosynthesis. Herein, we firstly overviewed the currently available first, second-, and third-line anti-TB medications together with the recently approved FDA treatments, then we reviewed the druggability of InhA as an important molecular target, the structure-activity relationship of its lead inhibitors and the emerging resistance mechanisms.

1.1. Currently available medications for the treatment of tuberculosis.

The drug-susceptible TB cases can be efficiently treated using a combination of three or four medications of the first-line drugs. The currently used regimen involves a two-month course of isoniazid (INH), rifampicin, pyrazinamide, and/or ethambutol, then a four-month course of both isoniazid and rifampicin^(6, 7). With the appearance of multidrug-resistant (MDR) as well as extensively drug-resistant (XDR)

Mycobacterium tuberculosis (*Mtb*) strains, there is a high need to discover novel medications (**Fig. 1**)^(6, 7).




Fig.1: Drug development for treatment of TB.

1.1.1. First-line anti-TB medications.**1.1.1.1. Isoniazid (INH).**

Isonicotinic acid hydrazide (INH) (**Fig. 2**) is a famous powerful antitubercular agent. It is a prodrug that must be activated by the bacterial catalase-peroxidase enzyme (KatG) present in *M. tuberculosis*, thus INH oxidation in the presence of NADH leads to covalent INH-NADH adducts formation which are powerful enoyl acyl carrier protein reductase (InhA) inhibitors that is involved in the synthesis of mycolic acids and are thus important for mycobacterial cell wall lipids synthesis⁽⁸⁾.

1.1.1.2. Rifampicin (RMP).

RMP (**Fig. 2**) has a strong bactericidal and sterilizing effect on *M. tuberculosis*. Although RMP is reported to interfere with RNA synthesis *via* binding to the RNA polymerase β subunit leading to inhibition of this enzyme⁽⁹⁾.

1.1.1.3. Pyrazinamide (PZA).

PZA (**Fig. 2**) is a prodrug requiring activation by the pyrazinamidase/nicotinamidase enzyme of *M. tuberculosis* to pyrazinoic acid. PZA exhibits several effects on *M.*

tuberculosis through inhibiting the synthesis of pantothenate and co-enzyme A, in addition to interfering with membrane energy production^(9, 10).

1.1.1.4. Ethambutol (EMB).

EMB (**Fig. 2**) inhibits the arabinosyl transferase enzyme (encoded by *embB*), interfering with the cell wall arabinogalactan biosynthesis. When arabinogalactan synthesis is disrupted, mycolic acids can't be transferred into the cell wall and the cell wall becomes more permeable^(9, 11).

1.1.2. Second-line anti-TB medications.

1.1.2.1. Fluoroquinolones.

Fluoroquinolones such as ciprofloxacin and levofloxacin (**Fig. 3**) have been found to inhibit the topoisomerase II (DNA gyrase) that catalyzes the DNA supercoiling^(12, 13).

1.1.2.2. Aminoglycosides.

Aminoglycosides such as kanamycin and amikacin (**Fig. 3**) can inhibit protein synthesis by alteration at the 16S rRNA level^(12, 14).




Fig. 2: First line antitubercular agents.




Fig. 3: Second line antitubercular agents.

1.1.3. Third-line anti-TB medications.

1.1.3.1. Bedaquiline.

Bedaquiline (**Fig. 4**) is the first member of a new class of drugs called diarylquinolines, which possess a novel mechanism of action. It inhibits the mycobacterial ATP synthase. Preclinical and clinical studies have shown that Bedaquiline has a potent activity against growing and non-growing mycobacterial populations, it is also active against MDR-TB strains ⁽¹⁵⁾.


1.1.3.2. Delamanid.

Delamanid (**Fig. 4**) is the first member of the dihydro-nitroimidazooxazole family to enter clinical trials. It is used along with other anti-tuberculosis medications for active multidrug-resistant tuberculosis. This drug works by inhibiting the mycolic acids production thus destabilizing the bacterial cell wall. Delamanid is a pro-drug that needs to be activated by the deazaflavin dependent nitroreductase enzyme. A reactive


intermediate metabolite, formed between delamanid and desnitro-imidazooxazole derivative, is known to play a critical role in mycolic acid biosynthesis inhibition ⁽¹⁶⁾.

1.1.4. Recently FDA-approved anti-TB combination.

In 2019, The U.S. Food and Drug Administration (FDA) approved Pretomanid Tablets in combination with bedaquiline and linezolid (**Fig. 5**) for the treatment of highly resistant TB of the lungs ⁽¹⁷⁾. Clinical studies revealed that the regimen of bedaquiline–pretomanid–linezolid showed 90% activity against highly drug-resistant TB, However, the adverse effects due to linezolid dose were unacceptable. The proper linezolid dose and the treatment duration were investigated in order to lower toxic effects while maintaining anti-TB potency, where linezolid is used for 26 weeks at a dose of 600 mg according to the general risk/benefit ratio favored regimen ⁽¹⁸⁾.




Bedaquiline




Delamanid

Fig. 4: Third line antitubercular agents.




Bedaquiline



pretomanid

inhibiting mycolic acid biosynthesis



linezolid

inhibiting protein synthesis

Fig. 5: Recent FDA anti-TB combination.

2. Resistance to the currently available anti-TB medications and their limitations.

Mycobacterium tuberculosis has been the leading global cause of human lethal infections and accounts lately for the greatest number of drug-resistant diseases by a single bacterial pathogen. Molecular mechanisms of drug resistance have been elucidated for the currently available medications. The two main resistance mechanisms are the mutation of certain drug-activating enzymes to prevent antitubercular drug activation or the alteration of the essential protein targets preventing the drug binding. Studying the drug resistance mechanisms in *Mycobacterium tuberculosis* could facilitate the development of novel anti-TB drugs ⁽⁵⁾. Moreover, Adverse effects are very common during the treatment of tuberculosis using the currently available medications. The most common drug-related adverse effects of anti-TB medications are listed in **Table 1** ^(16, 19-21).

Table 1: Common adverse effects of the currently available anti-TB medications.

Substance	Common adverse effects
Isoniazid (high dose)	Peripheral neuropathy, and hepatotoxicity
Rifampicin (high dose)	Renal, hepatic dysfunctions, and convulsions
Pyrazinamide	Hepatotoxicity, rash, and gout
Ethambutol	Optic neuropathy
Amikacin; Kanamycin	Ototoxicity, and nephrotoxicity
Levofloxacin; ciprofloxacin	GI disturbances, tendinitis, and insomnia
Bedaquiline	Disturb the heart and liver function
Delamanid	Disturb the heart function

3. Enoyl acyl carrier protein reductase (InhA enzyme) as a main target for treating TB.

Mycolic acids are essential components of the unique mycobacterial cell walls, which help to fight against dehydration as well as hydrophobic drugs ⁽²²⁾. Two discrete

pathways of Fatty Acid Synthase (FAS) systems are involved in mycolic acids biosynthesis; mainly the FASI system (Co-A dependent) and the FASII system (Acyl Carrier Protein dependent).

The FASI pathway involves de novo synthesis of the fatty acids *via* elongation of the acetyl group by two carbon units giving precursors of 14–26 carbon atoms by using malonyl Co-A and acetyl Co-A. Monofunctional enzymes in the FASII system extend the FASI products to form precursors of mycolic acids. Firstly, the generated precursors of FASI are transformed into β -ketoacyl derivatives through the use of β -ketoacyl-ACP-synthase. In the second step, the product is reduced by β -ketoacyl-ACP-reductase which is subsequently transformed into an unsaturated derivative in the presence of β -hydroxy acyl-ACP-dehydratase. In the final step, the enoyl acyl carrier protein reductase (InhA) catalyzes the fatty acyl substrate reduction to give mycolic acids ⁽²³⁾.

Interestingly, the FASII pathway enzymes do not exist in eukaryotes, thereby these enzymes would be safe and attractive clinically validated drug targets. One of these enzymes is InhA (**Fig. 6**) ⁽²⁴⁾ which is essential for the mycolic wall biosynthesis and the survival of mycobacterial cells. The inhibition of InhA enzyme stops fatty acid elongation in mycolate production leading to cell lysis ⁽²⁵⁾.





Fig. 6: 3D Representation of InhA enzyme in cartoon view.


The InhA active site involves the substrate binding loop (SBL: residues 197-226) as well as the NAD cofactor that interacts with the protein and the acyl substrate (or inhibitors) (26, 27). The InhA inhibitors include prodrugs such as INH which irreversibly interact with NAD forming an adduct (28), direct inhibitors like triazoles, diphenyl ethers, and triclosan involved in reversible binding to the NAD (29-31), or bulky inhibitors displacing the NAD like pyridomycin (32). Literature reports revealed that Tyr158 and Phe149 are the two key amino acids involved in the binding interactions (33).

INH is one of the most effective drugs inhibiting the InhA enzyme. INH is definitely a prodrug that needs to be converted to its active form, the isonicotinoyl radical, *via* an oxidative activation by the action of KatG enzyme (catalase-peroxidase). The isonicotinoyl radical permanently reacts with NAD cofactor forming an INH-NADH adduct that acts as the real InhA inhibitor (34). The 3D crystal structure of the InhA-isonicotinoyl complex shows that the adduct occupies a hydrophobic pocket (Fig. 7) (24, 35) which was validated as a main site to increase the inhibitory activity (36). Most of the INH

resistance is mainly caused by the KatG point mutations rather than InhA itself. The S315 mutation of KatG accounts for about 50–95% of INH-resistant clinical isolates. INH resistance can also occur through mutations in the InhA active site preventing INH-NAD complex binding. While the mutations in the InhA enzyme account for some resistance, the great majority of clinically observed INH resistance is attributed to KatG mutations (37). The INH resistance then directed efforts to discover direct inhibitors that can bypass the essential activation step of INH (38, 39). Among the introduced direct InhA inhibitors, triclosan (TCS) (Fig. 8) is a broad-spectrum antibacterial agent that was found in many pharmaceutical products. Unfortunately, TCS interferes with the endocrine function especially reproductive hormones which led to its withdrawal (40). TCS directly inhibits the InhA at low concentrations. The presence of three chlorine atoms on the TCS structure increases its lipophilicity while reducing its oral bioavailability leading to limiting its potential as an anti-tubercular medication (41). The triclosan-InhA crystal structure reveals



(a)



(b)

Fig. 7: (a) 2D and (b) 3D binding modes of isonicotinoyl-NADH complex inside InhA active site (PDB:1zid).

the engagement of the B-ring with both the Phe149 residue and the NADH cofactor nicotinamide group. H-bonding network was also observed between the TCS hydroxyl group and the ribose 2'-OH group of the NADH as well as the Tyr158 residue. In addition, the ether linkage forms a H-bond with the 2'-hydroxyl group of the ribose (Fig. 8a) ⁽⁷⁾. Interestingly, the X-ray crystal structure (PDB:1P45) conducted by Kuo et al. ⁽⁴²⁾ declared that two triclosan molecules exist within the InhA active site (Fig. 8b). This occurrence was presumably due to a larger InhA substrate binding loop that can accommodate a bigger substrate. One TCS molecule occupies the same orientation and space as that of the previously shown triclosan-InhA complex. While the second molecule lies close to the first, interacting with the substrate binding loop through Vander Waals interactions ⁽⁴²⁾.




Fig. 8: (a) Representation of the key interactions of triclosan (red) bound to the InhA binding site & (b) A view of two molecules of triclosan (red) within the active site. NAD⁺(magenta) and binding site residues (green).

Most of the InhA binding interactions are formed within the substrate-binding loop





which extended from residues 197 to 226. This binding loop was only partially ordered in the subunit containing a single triclosan molecule. The superposition of both subunits of the single-bound versus the double-bound forms demonstrated significant backbone deviations in the substrate-binding loops directly contacting the triclosan molecule. In addition, it was found that the second triclosan molecule stabilized the substrate-binding loop. This may be explained by the *M. tuberculosis* enzyme's specificity to accommodate long fatty acyl substrates (C16 and larger). Interestingly, the mycobacterial InhA enzyme has a special hydrophobic substrate-binding loop (residues 197–226) that is almost ten residues larger than the corresponding *E. coli* binding loop (residues 203–212) ⁽⁴²⁾.

Different classes of direct InhA enzyme inhibitors were identified including TCS and its derivatives ^(31, 34), triazoles ^(30, 43), GEQ analogs ⁽⁴⁴⁾, pyrazoles ^(33, 45), and sulfonamides ⁽⁴⁶⁾.

3.1. Triclosan analogs.

3.1.1. Expanded triclosan and di-triclosan derivatives.

The two molecules of triclosan unexpectedly found within the active site of mycobacterial InhA enzyme became the strategy basis for the development of larger InhA inhibitors. Thus, expanded triclosan analogs and di-triclosan derivatives **I-III** were investigated as novel InhA inhibitors and anti-TB agents. These ether-linked derivatives displayed an excellent enzyme inhibitory activity which is comparable with the parent triclosan, while exhibiting moderate to low anti-TB activity. These derivatives provide promising opportunities as leads for additional optimization ⁽⁷⁾.



A docking study of the di-triclosan derivative **III** (Fig. 9) ⁽⁷⁾ revealed that phenyl rings of the docked molecule formed π - π stacking interaction with both Phe149 and the NAD cofactor. In addition, it displayed a hydrogen bond interaction between the hydroxyl group and the cofactor. Favorable Vander Waals interactions were also observed between the phenyl moiety and amino acids Ile215 and Leu218 ⁽⁷⁾.





Fig. 9: Representation of the key interactions of compound III (blue) within the InhA binding site. NAD (green) and the binding site residues (brown).

3.1.2. Triclosan-based macrocyclic derivatives.


Based on the unexpected presence of two triclosan molecules at the InhA active site, novel macrocyclic derivatives were also investigated as inhibitors of InhA enzyme ⁽³⁴⁾. These biaryl ether derivatives **IV** & **V** are the first macrocyclic direct InhA inhibitors that can bind to the active site exhibiting

promising inhibitory activity. In addition, these macrocyclic compounds demonstrated a good antitubercular potency against *M. tuberculosis H37Rv* strain relative to that of the parent triclosan ⁽³⁴⁾.

The docking study of compound **V** showed that this molecule was embedded deeply within the hydrophobic pocket near the cofactor with the bottom OH group directed to the other side away from Tyr158. This OH group displayed strong hydrogen bond interactions with both ribose and phosphate groups of the cofactor ⁽³⁴⁾.



%Inhibition (50 μ M)= 52
MIC= 20 μ g/ml




%Inhibition (50 μ M)= 93
MIC= 40 μ g/ml


Triclosan (%Inhibition (50 μ M)= 100; MIC= 20 μ g/ml)

3.2. 1,4-Disubstituted-1,2,3-triazoles.


1,4-Disubstituted-1,2,3-triazoles are readily accessible *via* the azide-alkyne cycloaddition, in addition to their excellent stability and biological activity which rendered them promising drug core structures. Thus, the new strategies to synthesize compounds containing fused triazole derivatives are highly desirable ⁽⁴⁷⁾.



VI
%Inhibition (50 μ M)= 25
MIC= 25 μ g/ml



VII
%Inhibition (50 μ M)= 46
MIC= 10 μ g/ml



VIII
%Inhibition (50 μ M)= 58
MIC= 5 μ g/ml

3.2.1. α -Ketotriazoles and 1,4-dialkyl-substituted triazoles.


α -Ketotriazole derivative **VI** and 1,4-dialkyl-substituted triazoles **VII** & **VIII** were found to exhibit moderate InhA inhibitory activity as well as high antitubercular potency. It was observed that compounds having long alkyl chains showed the highest InhA inhibitory activity among these derivatives. The addition of lipophilic chains could promote more hydrophobic interactions with the enzyme pocket. In addition, this lipophilic chain which mimics the natural InhA substrate led to an increase in the binding affinity toward InhA enzyme⁽⁴³⁾

3.2.2. Chromone based 1,2,3-triazole derivatives.


Chromone derivatives are frequently found in several therapeutically active medications such as anti-inflammatory and anti-microbial agents⁽⁴⁸⁻⁵⁰⁾. In addition, 1,2,3-triazole-embedded heterocyclic derivatives displayed various biological activities, especially anti-mycobacterial activity⁽⁵¹⁻⁵⁴⁾. It was reported that chromone-linked 1,2,3-triazole analogs **IX-XII** showed a high inhibitory efficiency with MIC values ranging from 1.56 to 6.25 μ g/ml against the *Mycobacterium tuberculosis H37Rv*⁽⁴⁷⁾.

The preliminary structure-activity relationship studies of the chromone-linked triazoles revealed that compounds possessing bulky substituents such as 4-*tert*-butylphenyl group (compound **IX**) exhibited excellent antitubercular activity. In addition, the introduction of large aliphatic substituents (mimicking the InhA substrate) potentiated the activity as demonstrated by compounds **X**


& **XI**⁽⁴⁷⁾. Also, it has been reported that combining the diaryl ethers with the chromone-based triazoles to obtain a hybrid structure (compound **XII**) led to the enhancement of antitubercular potency⁽³⁰⁾. The docking studies revealed that chromone-based triazoles possessed promising binding




IX
MIC= 3.125 μ g/ml



X
MIC= 6.25 μ g/ml



XI
MIC= 1.56 μ g/ml



XII
MIC= 0.6 μ g/ml

scores toward InhA enzyme when compared with the other target proteins. Compound **IX** formed π - π stacking with Phe149 (**Fig. 10**)⁽²⁴⁾. Similarly, compound **XI** displayed π - π interaction with both Trp222 and Tyr158 amino acids (**Fig. 11**)⁽²⁴⁾. These results indicate that π - π interaction could enhance the docking scores⁽⁴⁷⁾.

3.2.3. 1-Phenyl-4-substituted-1,2,3-triazole derivatives.

It was observed that the 1-phenyl 1,2,3-triazole analogs **XIII-XVI** displayed variable inhibitory activities against the *Mycobacterium tuberculosis H37Rv* strain. The substitution at the 4-position of the triazole ring was found to exhibit a major effect on antitubercular activity. Thus, it could be concluded that the reactivity order




Fig. 10: Representation of the key interactions of compound IX within the InhA binding site.






Fig. 11: Representation of the key interactions of compound XI within the InhA binding site.

of these substituents was isonicotinoyl hydrazide > CHO > vinyl > CH₂OH. Additionally, it is assumed that isonicotinoyl hydrazides **XIIIA** & **XIIIB** may have fewer side effects and lower toxicity than INH itself due to the protection of the highly reactive hydrazine group in these derivatives. Moreover, the structure-activity relationship study demonstrated that compounds having electron-withdrawing substituents such as 4-Cl or 4-NO₂ at *N*-phenyl moiety showed superior activity among this series⁽⁵⁵⁾.



3.2.4. 1,2,3-Triazole incorporated benzothiazinone derivatives


Benzothiazinone incorporated 1,2,3-triazoles **XVII-XIX** were found to be promising inhibitors of *Mycobacterium tuberculosis* H37Ra. According to the structure-activity relationship study, the inhibitory activity depends on the type of substituents as well as their position on the phenyl ring. Both compounds **XVII** (possessing *p*-F) and **XVIII** (possessing *m*-Cl) exhibited moderate antitubercular activities with MIC values 29.24 and 27.34 µg/ml, respectively. Furthermore, changing the substituent position on the phenyl ring greatly affects the antitubercular activity. The introduction of the chloro substituent at the ortho position readily reduces the activity as demonstrated by compound **XIX** (MIC >30 µg/ml)⁽⁵⁶⁾.



3.3. Fluorene derivatives.

Genz-10850 molecule (also called GEQ) and GEQ analogs were identified as very promising InhA inhibitors. Although GEQ is a strong InhA inhibitor, it has a low potency against *M. tuberculosis* due to its limited permeability or the efflux pump's activation⁽⁵⁷⁾. Hence, GEQ was chemically modified to

potentiate its poor biological activity through improving its membrane permeability or inhibiting the efflux pumps ⁽⁴⁴⁾. By substituting the phenyl group (compound **XX**) with an indole ring, the GEQ activity was significantly increased. In order to guarantee comparable binding interactions with the InhA binding site, the global GEQ scaffold (presence of fluorene moiety and piperidine carboxamide) was retained. In addition, compound **XXI**, which has an extra hexyloxy group on the fluorene part, exhibited the highest activity against both *M. tuberculosis* growth and InhA enzyme. This alkyl group would increase the molecule's activity and most likely facilitate more hydrophobic contacts with the binding site by somewhat imitating the native substrate. Interestingly, reserpine, verapamil, or carbonyl cyanide m-chlorophenylhydrazone (CCCP) are efflux pump inhibitors that enhanced the antitubercular activity of Genz-10850 (GEQ) and its derivatives. These findings supported the hypothesis that some efflux pump might be responsible for effluxing GEQ as well as its derivatives out of the mycobacterial cell ⁽⁴⁴⁾.




3.4. 1,3-Diphenyl pyrazole derivative.

Pyrazoles and their analogs are regarded as pharmacologically active agents which display nearly all pharmacological actions, they are also documented for their potent antitubercular activity ⁽⁵⁸⁻⁶⁰⁾. Hence, pyrazoles are a promising choice for synthesizing new antitubercular agents.

3.4.1. Pyrazolourea derivatives.

Pyrazolourea conjugates were reported to exhibit promising inhibitory activity against *Mycobacterium tuberculosis H37Ra*. The structure-activity relationship study revealed that the basic skeleton 1,3-diphenyl pyrazole scaffold is observed to possess remarkable antitubercular activity *via* InhA inhibition. Moreover, the substitution of the *p*-position of the *N*-phenyl urea with an electron-withdrawing group such as halogen or nitro substituent (compounds **XXII** & **XXIII**) greatly enhanced the antitubercular activity ⁽³³⁾.




3.4.2. Pyrazole embedded pyrazine derivatives.


It was observed that pyrazole-linked pyrazine analogs **XXIV-XXVI** showed remarkable antitubercular efficiency with MIC values ranging from 0.78 to 3.12 μ g/ml. It was found that the substitution of the phenyl group at C3 of the pyrazole ring with a halogen atom led to prominent improvement in the inhibitory activity as demonstrated by compounds **XXV** and **XXVI** which displayed the highest potency among this series. This effect was attributed to the increase in lipophilicity of these compounds ⁽⁶¹⁾.

3.4.3. Pyrazole incorporated thiazolo[3,2-*a*]pyrimidones derivatives.

1,3-Diphenyl pyrazole derivatives were found to exhibit potential anti-TB efficiency. Regarding the structure-activity relationship study, substitutions at the 1-phenyl group




may not be favorable for the activity. Hence, it should be kept as unsubstituted. Moreover, the position of substituents at the 3-phenyl group significantly affected the antitubercular activity, compound **XXVII** possessing *p*-methyl exhibited the least activity among this series. while methyl substitution at the ortho (compound **XXVIII**) or meta-position (compounds **XXIX** & **XXX**) of the 3-phenyl group displayed a favorable effect and a prominent enhancement in the inhibitory activity. In *M. tuberculosis H37Rv* screening, the most active derivative, compound **XXIX**, exhibited a minimum inhibitory concentration of 1.9 $\mu\text{g/ml}$. This compound also showed an excellent synergistic effect with the first and second-line medications used in tuberculosis screening ^(62, 63).




3.4.4. pyrazole-linked benzothiazole analogs.

It was reported that pyrazole-linked benzothiazole derivatives possessed excellent antitubercular potency. According to the structure-activity relationship investigation, compounds that have benzothiazole and pyrazole groups linked *via* hydrazine linkage **XXXI** & **XXXII** (MIC values 1.6 $\mu\text{g/ml}$) displayed the best activity compared with those possessing a carbohydrazide linkage **XXXIII** (MIC values 25 $\mu\text{g/ml}$). Regarding the hydrazine-linked derivatives, derivatives having *p*-CH₃ and *p*-Cl (compounds **XXXI** & **XXXII**, respectively) displayed the best anti-TB activity among this series ⁽⁴⁵⁾.




3.5. Sulfonamide derivatives.


A series of sulfonamides has been developed as novel nanomolar InhA inhibitors *via* fragment-based design. Sulfonamide derivatives substituted with an aryl group such as *tert*-butyl phenyl (compound **XXXIV**) showed low activity against InhA enzyme. Replacing the aryl moiety with heterocyclic rings in compounds **XXXV** and **XXXVI** increased the InhA inhibitory activity. Moreover, compound **XXXVII** having a halogen atom and methyl substituent exhibited the highest activity among all tested derivatives ⁽⁴⁶⁾.




XXXIV

%Inhibition (100 μ M) = 40

XXXV

%Inhibition (100 μ M) = 66IC₅₀ = 22 μ M

XXXVI

%Inhibition (100 μ M) > 90IC₅₀ = 6 μ M

XXXVII

%Inhibition (100 μ M) > 90IC₅₀ = 0.25 μ M

4. Future prospects.

The first-line anti-TB medication; isoniazid effectively inhibits InhA enzyme which is considered a crucial enzyme in mycolic acid biosynthesis. INH is a prodrug that forms NAD-INH adduct after being activated by the mycobacterial catalase-peroxidase KatG. Despite INH prominence as the most powerful antitubercular agent, mechanistic investigations revealed that KatG mutation is the main cause of INH resistance due to impaired activation. Thus, efforts are directed toward finding inhibitors that can skip the crucial activation step of INH. One of the newly developed direct InhA inhibitors is triclosan which is a broad-spectrum antibiotic with a promising InhA inhibitory profile. However, because of its poor absorption and endocrine toxicity, triclosan can't be used as an antitubercular drug. Furthermore, different classes of novel antitubercular agents and potential direct InhA inhibitors were developed in order to overcome resistance such as expanded triclosan analogs, 1,2,3-triazoles, fluorene derivatives in addition to pyrazoles.

Author's contributions: M.M.S:

Conceptualization, writing, and editing the draft;

H.M.R. & M.T.: Writing the draft; M.A.M.:

Supervision and reviewing.

Funding: No fund.

Data Availability Statement: The data presented are available on request from the corresponding authors.

Conflict interest statement: The authors declare no conflict of interest.

References:

- (1) Velankar H. Tuberculous Otitis Media with Facial Paralysis-Case Report and Review of Literature. *Otolaryngology Open Access Journal*. 2018;3(2).
- (2) <https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis>, accessed in February 2023.
- (3) Konstantinos A. Diagnostic tests: Testing for tuberculosis. *Australian Prescriber*. 2010;33(1):12-8.
- (4) Dye C, Scheele S, et al, Dolin P, Pathania V, Raviglione MC. Global Burden of Tuberculosis. *JAMA*. 1999;282(7):677.
- (5) Zhang YaY, W. Mechanisms of drug resistance in Mycobacterium tuberculosis. *The International Journal of Tuberculosis and Lung Disease*. 2009;13(11):1320-30.
- (6) B. Jadhav S, Fatema S, S. Bhagat S, Farooqui M. Thiazolo[3,2-a] Pyrimidones as a Novel Anti-TB Agents. 2018;55:2893-900.
- (7) Chetty S, Armstrong T, Sharma Kharkwal S, Drewe WC, De Matteis CI, Evangelopoulos D, et al. New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis. *Pharmaceuticals (Basel)*. 2021;14(4):361.
- (8) Timmins GS, Deretic V. Mechanisms of action of isoniazid. *Molecular Microbiology*. 2006;62(5):1220-7.
- (9) Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2015;19(11):1276-89.
- (10) Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. *The international journal of tuberculosis and lung disease*. 2003;7(1):6-21.
- (11) Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. *Antimicrob Agents Chemother*. 1989;33(9):1493-9.

- (12) Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel, Switzerland). 2014;3(3):317-40.
- (13) Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother. 2004;48(4):1281-8.
- (14) Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42(5):1295-7.
- (15) Deoghare S. Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis. Indian journal of pharmacology. 2013;45(5):536-7.
- (16) Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis. Journal of pharmacology & pharmacotherapeutics. 2014;5(3):222-4.
- (17) [https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,\(TB\)%20of%20the%20lungs](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,(TB)%20of%20the%20lungs), accessed in February 2023.
- (18) Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. New England Journal of Medicine. 2022;387(9):810-23.
- (19) Gualano G, Capone S, Matteelli A, Palmieri F. New antituberculosis drugs: from clinical trial to programmatic use. Infectious Disease Reports. 2016;8(2):6569.
- (20) Sridhar A, Sandeep Y, Krishnakishore C, Sriramnaveen P, Manjusha Y, Sivakumar V. Fatal poisoning by isoniazid and rifampicin. Indian J Nephrol. 2012;22(5):385-7.
- (21) Fox GJ, Menzies D. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infectious Diseases and Therapy. 2013;2(2):123-44.
- (22) De Souza MVN, Ferreira MdL, Pinheiro AC, Saraiva MF, de Almeida MV, Valle MS. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis. The scientific world journal. 2008;8:720-51.
- (23) Prasad MS, Bhole RP, Khedekar PB, Chikhale RV. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery. Bioorganic Chemistry. 2021;115:105242.
- (24) 2019 MOE. <https://www.chemcomp.com/Products.htm>.
- (25) Matviuk T, Madacki J, Mori G, Orena BS, Menendez C, Kysil A, et al. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. European journal of medicinal chemistry. 2016;123:462-75.
- (26) Kamsri P, Hanwarinroj C, Phusi N, Pornprom T, Chayajarus K, Punkvang A, et al. Discovery of new and potent inha inhibitors as antituberculosis agents: structure-based virtual screening validated by biological assays and x-ray crystallography. Journal of chemical information and modeling. 2019;60(1):226-34.
- (27) Kuldeep J, Sharma SK, Sharma T, Singh BN, Siddiqi MI. Targeting Mycobacterium Tuberculosis Enoyl-Acyl Carrier Protein Reductase Using Computational Tools for Identification of Potential Inhibitor and their Biological Activity. Molecular Informatics. 2021;40(5):2000211.
- (28) Hassan S, Sudhakar V, Mary MBN, Babu R, Doble M, Dadar M, et al. Computational approach identifies protein off-targets for Isoniazid-NAD adduct: hypothesizing a possible drug resistance mechanism in Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics. 2019;38(6):1697-710.
- (29) Ibrahim TS, Taher ES, Samir E, M Malebari A, Khayyat AN, Mohamed MF, et al. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors. Molecules. 2020;25(14):3125.
- (30) Chebaiki M, Delfourne E, Tamhaev R, Danoun S, Rodriguez F, Hoffmann P, et al. Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA. European Journal of Medicinal Chemistry. 2023;259:115646.
- (31) Tamhaev R, Grosjean E, Ahamed H, Chebaiki M, Rodriguez F, Recchia D, et al. Exploring the plasticity of the InhA substrate-binding site using new diaryl ether inhibitors. Bioorganic Chemistry. 2024;143:107032.
- (32) Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Horlacher OP, et al. Pyridomycin bridges the NADH-and substrate-binding pockets of the enoyl reductase InhA. Nature chemical biology. 2014;10(2):96-8.
- (33) Shaaban MM, Teleb M, Ragab HM, Singh M, Elwakil BH, A. Heikal L, et al. The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy. Bioorganic Chemistry. 2024;145:107179.

- (34) Rodriguez F, Saffon N, Sammartino JC, Degiacomi G, Pasca MR, Lherbet C. First triclosan-based macrocyclic inhibitors of InhA enzyme. *Bioorganic chemistry*. 2020;95:103498.
- (35) Rozwarski DA. Modification of the NADH of the Isoniazid Target (InhA) from *Mycobacterium tuberculosis*. *Science (New York, NY)*. 1998;279(5347):98-102.
- (36) Tonge P, Kisker C, Slayden R. Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of *Mycobacterium tuberculosis*. *Current Topics in Medicinal Chemistry*. 2007;7(5):489-98.
- (37) Zhang Y, Yew W. Mechanisms of drug resistance in *Mycobacterium tuberculosis*: update 2015. *The International Journal of Tuberculosis and Lung Disease*. 2015;19(11):1276-89.
- (38) Volynets GP, Tukalo MA, Bdzhola VG, Derkach NM, Gumeniuk MI, Tarnavskiy SS, et al. Novel isoniazid derivative as promising antituberculosis agent. *Future Microbiology*. 2020;15(10):869-79.
- (39) Atta A, Fahmy S, Rizk O, Sriram D, Mahran MA, Labouta IM. Structure-based design of some isonicotinic acid hydrazide analogues as potential antitubercular agents. *Bioorg Chem*. 2018;80:721-32.
- (40) Rožman K, Sosič I, Fernandez R, Young RJ, Mendoza A, Gobec S, et al. A new 'golden age' for the antitubercular target InhA. *Drug discovery today*. 2017;22(3):492-502.
- (41) Vosátka R, Krátký M, Vinšová J. Triclosan and its derivatives as antimycobacterial active agents. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2018;114:318-31.
- (42) Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, et al. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. *The Journal of biological chemistry*. 2003;278(23):20851-9.
- (43) Menendez C, Gau S, Lherbet C, Rodriguez F, Inard C, Pasca MR, et al. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. *European journal of medicinal chemistry*. 2011;46(11):5524-31.
- (44) Chollet A, Mori G, Menendez C, Rodriguez F, Fabing I, Pasca MR, et al. Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and *Mycobacterium tuberculosis* growth. *European journal of medicinal chemistry*. 2015;101:218-35.
- (45) Bhat M, Belagali SL. Synthesis, characterization and biological screening of pyrazole-conjugated benzothiazole analogs. *Future medicinal chemistry*. 2018;10(1):71-87.
- (46) Sabbah M, Mendes V, Vistal RG, Dias DM, Záhorská M, Mikusova K, et al. Fragment-based design of *Mycobacterium tuberculosis* InhA inhibitors. *Journal of medicinal chemistry*. 2020;63(9):4749-61.
- (47) Nalla V, Shaikh A, Bapat S, Vyas R, Karthikeyan M, Yogeewari P, et al. Identification of potent chromone embedded [1,2,3]-triazoles as novel anti-tubercular agents. *Royal Society open science*. 2018;5(4):171750.
- (48) Gaspar A, Matos MJ, Garrido J, Uriarte E, Borges F. Chromone: A Valid Scaffold in Medicinal Chemistry. *Chemical Reviews*. 2014;114(9):4960-92.
- (49) Keri RS, Budagumpi S, Pai RK, Balakrishna RG. ChemInform Abstract: Chromones as a Privileged Scaffold in Drug Discovery: A Review. *ChemInform*. 2014;45(27):340-74.
- (50) Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. *Journal of Medicinal Chemistry*. 2017;60(19):7941-57.
- (51) de Carvalho da Silva F, Cardoso MFdC, Ferreira PG, Ferreira VF. Biological Properties of 1H-1,2,3- and 2H-1,2,3-Triazoles. *Topics in Heterocyclic Chemistry: Springer International Publishing*; 2014. p. 117-65.
- (52) Xu Z, Song X-F, Hu Y-Q, Qiang M, Lv Z-S. Azide-alkyne cycloaddition towards 1H-1,2,3-triazole-tethered gatifloxacin and isatin conjugates: Design, synthesis and in vitro anti-mycobacterial evaluation. *European Journal of Medicinal Chemistry*. 2017;138:66-71.
- (53) Zhang S, Xu Z, Gao C, Ren Q-C, Chang L, Lv Z-S, et al. Triazole derivatives and their anti-tubercular activity. *European Journal of Medicinal Chemistry*. 2017;138:501-13.
- (54) Zhou B, He Y, Zhang X, Xu J, Luo Y, Wang Y, et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. *Proceedings of the National Academy of Sciences*. 2010;107(10):4573-8.
- (55) Boechat N, Ferreira VF, Ferreira SB, Ferreira MdLG, da Silva FdC, Bastos MM, et al. Novel 1, 2, 3-triazole derivatives for use against *Mycobacterium tuberculosis* H37Rv (ATCC 27294) strain. *Journal of medicinal chemistry*. 2011;54(17):5988-99.
- (56) Shaikh MH, Subhedar DD, Arkile M, Khedkar VM, Jadhav N, Sarkar D, et al. Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent. *Bioorganic & medicinal chemistry letters*. 2016;26(2):561-9.
- (57) He X, Alian A, Ortiz de Montellano PR. Inhibition of the *Mycobacterium tuberculosis* enoyl acyl

- carrier protein reductase InhA by arylamides. *Bioorganic & medicinal chemistry*. 2007;15(21):6649-58.
- (58) Karrassi K, Radi S, Ramli Y, Taoufik J, Mabkhot Y, Al-aizari F, et al. Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. *Molecules*. 2018;23(1):134.
- (59) Pathak RB, Chovatia PT, Parekh HH. Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. *Bioorganic & Medicinal Chemistry Letters*. 2012;22(15):5129-33.
- (60) Xu Z, Gao C, Ren Q-C, Song X-F, Feng L-S, Lv Z-S. Recent advances of pyrazole-containing derivatives as anti-tubercular agents. *European Journal of Medicinal Chemistry*. 2017;139:429-40.
- (61) Hassan NW, Saudi MN, Abdel-Ghany YS, Ismail A, Elzahhar PA, Sriram D, et al. Novel pyrazine based anti-tubercular agents: design, synthesis, biological evaluation and in silico studies. *Bioorganic chemistry*. 2020;96:103610.
- (62) Jadhav SB, Fatema S, Bhagat SS, Farooqui M. Thiazolo[3,2- a] Pyrimidones as a Novel Anti-TB Agents. *Journal of Heterocyclic Chemistry*. 2018;55(12):2893-900.
- (63) Jadhav SB, Fatema S, Sanap G, Farooqui M. Antitubercular Activity and Synergistic Study of Novel Pyrazole Derivatives. *Journal of Heterocyclic Chemistry*. 2018;55(7):1634-44.